Childhood acute myeloid leukemia (AML) is a heterogeneous disease, in terms of genetic/molecular abnormalities resulting into marked differences in outcome. 1 A myriad of proteins have been suggested aberrantly regulated in AML, and Ets-related gene (ERG, 21q22) expression in normal and aberrant hematopoiesis is currently under evaluation. 2 High ERG expression has been associated with poor prognosis in cytogenetically normal adult AMLs. 3,4 Only recently, Staffas et al reported that ERG expression was associated with an inferior probability of event-free survival (EFS) in northern European children with AML, although not as independent prognostic factor. 5 We measured ERG expression in a cohort of 268 Italian pediatric patients (141 males and 127 females, median age at diagnosis 6 years, range 7 days-22 years) with newly diagnosed de novo AML enrolled in AIEOP LAM-2002 protocol. 6 ERG expression, relative to ABL, was measured by real-time quantitative-PCR and calculated the relative quantity (RQ) by the comparative ⌬⌬Ct method. ERG expression turned out to be higher (high-ERG, RQ Ͼ 1) or lower (low-ERG, RQ Ͻ 1) in AML patients, dividing them into 2 groups significantly different (N high-ERG ϭ 162, RQ ϭ 4927, N low-ERG ϭ 106, RQ ϭ 0371, P ϭ .007). Patients were then divided into cytogenetic groups. Of these, 157 carried well-known molecular markers, such as Core Binding Factor (CBF) anomalies (n ϭ 52), FLT3-ITD (n ϭ 34) and the mixed-lineage leukemia gene (MLL) rearrangements (n ϭ 71), whereas the remaining 111 patients were cytogenetically normal (CN). ERG was found to be different expressed between each AML subgroups, with statistical significance for all the subgroups analyzed ( Figure 1A , Student t test, statistical significance P Ͻ .05). Overall Survival (OS), defined as the time from diagnosis to last follow-up or death, was measured. Results showed no statistical difference in OS for CN (Kaplan-Meier log-rank test, P ϭ .58), CBF (P ϭ .82), nor FLT3ITD (P ϭ .54) patients according to ERG expression. By contrast, OS and EFS for patients with MLL-rearrangements and high-ERG expression were found to be significantly worse than those of patients with low-ERG (P Ͻ .001, Figure 1B ) expression. Multivariate analysis by Cox regression model confirmed that high-ERG expression is an independent prognostic factor for EFS in MLL-rearranged patients (hazard risk ϭ 4.22, 95% CI ϭ 1.10-16.18, P ϭ .036). In multivariate analysis complex karyotype remained the only other independent adverse factor in this group (P ϭ .028, HR ϭ 3.51, 95%CI ϭ 1.15-10.74). These data indicate that ERG expression strongly influences the probability of OS and EFS of MLL-rearranged patients. Since childhood MLL-rearranged AML includes patients with marked differences in biology and outcome, 7,8 we suggest the use of ERG expression to stratify patient's prognostic risk and to tailor therapeutic approaches. 
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Response:
High ERG gene expression is an unfavorable prognostic marker in pediatric acute myeloid leukemia
It is with great interest we read the scientific letter by Pigazzi et al and their finding that high ERG expression is an independent unfavorable prognostic marker for both event-free and overall survival in pediatric acute myeloid leukemia (AML) with MLL (11q23) rearrangement treated within the AIEOP LAM-2002 protocol. 1 As the authors also point out, our recent study on pediatric AML patients enrolled in the NOPHO-1993 or NOPHO-2004 protocols supports this finding. 2 We could show that high ERG expression is an unfavorable prognostic marker for event-free survival in this cohort of pediatric AML, where patients with MLL rearrangement were included. 2 And indeed, this observation was even more pronounced if we analyzed the group of patients with MLL rearrangement separately for event free survival ( Figure 1A , P ϭ .03). However, there was no significant difference between low and high ERG expression for overall survival in this group (P ϭ .16). High ERG expression was not identified as an independent marker in our study but this was mainly because BAALC and ERG were often found coexpressed at high levels, where high BAALC expression came out as a stronger predictor for prognosis in the multivariate analysis when the whole pediatric AML cohort was included. But, importantly, high BAALC was not statistically significant for event-free survival within the subgroup with MLL rearrangement ( Figure 1B , P ϭ .43) in contrast to ERG. There were too few patients in the MLL group (n ϭ 40) in our study to perform a meaningful multivariate analysis, so we cannot comment on the independence of the ERG expression. However, we think that these 2 separate studies now have strengthened the evidence that also high expression level of ERG is an unfavorable prognostic marker in pediatric AML, in particular for the important group of patients with MLL rearrangements. The remaining challenge before gene expression levels can be used for prognostic stratification for clinical use is to establish standardized methods for quantitative 
